Review of inhaled iloprost for the control of pulmonary artery hypertension in children

References

• BeghettiMCongenital heart disease and pulmonary hypertensionRev Port Cardiol200423227328115116461
   PubMedGoogle Scholar
• HaworthSGThe management of pulmonary hypertension in childrenArch Dis Child200893762062518381346
   PubMedGoogle Scholar
• BeghettiM[Pulmonary arterial hypertension in children: new therapeutic approaches]Ann Fr Anesth Reanim200726657057517524605
   PubMedGoogle Scholar
• HumbertMSitbonOSimonneauGTreatment of pulmonary arterial hypertensionN Engl J Med200430;351141425143615459304
   PubMed Web of Science ®Google Scholar
• RashidAIvyDSevere paediatric pulmonary hypertension: new management strategiesArch Dis Child2005901929815613526
   PubMedGoogle Scholar
• RosenzweigEBBarstRJPulmonary arterial hypertension in children: a medical updateCurr Opin Pediatr200820328829318475097
   PubMedGoogle Scholar
• GalieNTorbickiABarstRDartevellePHaworthSHigenbottamTGuidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of CardiologyEur Heart J200425242243227815589643
   PubMed Web of Science ®Google Scholar
• RubinLJMendozaJHoodMMcGoonMBarstRWilliamsWBTreatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trialAnn Intern Med199011274854912107780
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalieNNaeijeRRichSBourgeRCContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary hypertensionAm J Respir Crit Care Med20021651511779720
   PubMedGoogle Scholar
• OlschewskiHSimonneauGGalieNHigenbottamTNaeijeRRubinLJInhaled iloprost for severe pulmonary hypertensionN Engl J Med2002347532232912151469
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonORobbinsIMFrostATapsonVFEffects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet200135892881119112311597664
   PubMed Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJGalieNBlackCMKeoghABosentan therapy for pulmonary arterial hypertensionN Engl J Med20023461289690311907289
   PubMed Web of Science ®Google Scholar
• GalieNOlschewskiHOudizRJTorresFFrostAGhofraniHAAmbrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Circulation2008117233010301918506008
   PubMed Web of Science ®Google Scholar
• GalieNGhofraniHATorbickiABarstRJRubinLJBadeschDSildenafil citrate therapy for pulmonary arterial hypertensionN Engl J Med2005353202148215716291984
   PubMed Web of Science ®Google Scholar
• BeghettiMCurrent treatment options in children with pulmonary arterial hypertension and experiences with oral bosentanEur J Clin Invest200636Suppl 3162416919006
   PubMedGoogle Scholar
• YungDWidlitzACRosenzweigEBKersteinDMaislinGBarstRJOutcomes in children with idiopathic pulmonary arterial hypertensionCirculation2004110666066515289375
   PubMed Web of Science ®Google Scholar
• BarstRJMaislinGFishmanAPVasodilator therapy for primary pulmonary hypertension in childrenCirculation19;9991197120810069788
   PubMedGoogle Scholar
• MoncadaSGryglewskiRBuntingSVaneJRAn enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature19762635579663665802670
   PubMed Web of Science ®Google Scholar
• MoncadaSVaneJRArachidonic acid metabolites and the interactions between platelets and blood-vessel wallsN Engl J Med19793002011421147219340
   PubMedGoogle Scholar
• GrantSMGoaKLIloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation proceduresDrugs19924368899241379160
   PubMed Web of Science ®Google Scholar
• VaneJRBottingRMPharmacodynamic profile of prostacyclinAm J Cardiol19957533A10A
   PubMed Web of Science ®Google Scholar
• SchermulyRTYilmazHGhofraniHAWoydaKPullamsettiSSchulzAInhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertensionAm J Respir Crit Care Med2005172335836315879421
   PubMed Web of Science ®Google Scholar
• SchermulyRTKreisselmeierKPGhofraniHASamiduraiAPullamsettiSWeissmannNAntiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertensionCirc Res20049481101110815031263
   PubMed Web of Science ®Google Scholar
• HildebrandMPharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patientsEur J Clin Pharmacol199753151569349930
   PubMedGoogle Scholar
• AiroPRossiMScarsiMDanieliEGrottoloAZambruniADisease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control groupClin Exp Rheumatol200725572272718078620
   PubMedGoogle Scholar
• WalmrathDSchermulyRPilchJGrimmingerFSeegerWEffects of inhaled versus intravenous vasodilators in experimental pulmonary hypertensionEur Respir J1997105108410929163651
   PubMedGoogle Scholar
• SchermulyRTPullamsettiSSBreitenbachSCWeissmannNGhofraniHAGrimmingerFIloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungsRespir Res20078417257398
   PubMedGoogle Scholar
• SchermulyRTSchulzAGhofraniHABreitenbachCSWeissmannNHildebrandMComparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance developmentJ Aerosol Med200619335336317034310
   PubMedGoogle Scholar
• OlschewskiHGhofraniHASchmehlTWinklerJWilkensHHoperMMInhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study GroupAnn Intern Med20;132643544310733442
   PubMedGoogle Scholar
• OlschewskiHWalmrathDSchermulyRGhofraniAGrimmingerFSeegerWAerosolized prostacyclin and iloprost in severe pulmonary hypertensionAnn Intern Med199612498208248610951
   PubMed Web of Science ®Google Scholar
• McLaughlinVVOudizRJFrostATapsonVFMuraliSChannickRNRandomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med2006174111257126316946127
   PubMed Web of Science ®Google Scholar
• SchermulyRTKrupnikETenorHSchudtCWeissmannNRoseFCoaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivityAm J Respir Crit Care Med200116491694170011719312
   PubMed Web of Science ®Google Scholar
• SchermulyRTLeuchteHGhofraniHAWeissmannNRoseFKohstallMZardaverine and aerosolised iloprost in a model of acute respiratory failureEur Respir J200322234234712952271
   PubMedGoogle Scholar
• GhofraniHARoseFSchermulyRTOlschewskiHWiedemannRKreckelAOral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertensionJ Am Coll Cardiol200342115816412849677
   PubMed Web of Science ®Google Scholar
• SchermulyRTGhofraniHAEnkeBWeissmannNGrimmingerFSeegerWLow-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertensionAm J Respir Crit Care Med19;160(5 Pt 1):1500150610556112
   PubMedGoogle Scholar
• BeghettiMBernerMRimensbergerPCLong term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusionHeart2001863E1011514501
   PubMedGoogle Scholar
• BeghettiMNicodLBarazzone-ArgiroffoCRimensbergerPCNew combined treatments avoided transplantation in a child with severe pulmonary hypertensionHeart200490215414729784
   PubMedGoogle Scholar
• TissieresPNicodLBarazzone-ArgiroffoCRimensbergerPCBeghettiMAerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertensionAnn Thorac Surg2004783e48e5015337084
   PubMedGoogle Scholar
• IvyDDDoranAKSmithKJMalloryGBJrBeghettiMBarstRJShort- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertensionJ Am Coll Cardiol200851216116918191742
   PubMed Web of Science ®Google Scholar
• ZwisslerBKemmingGHableroKleenMMerkelMHallerMInhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndromeAm J Respir Crit Care Med1996154167116778970353
   PubMed Web of Science ®Google Scholar
• OlschewskiHGhofraniHAWalmrathDTemmesfeld-WollbruckBGrimmingerFSeegerWRecovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprostIntensive Care Med19982466316349681789
   PubMed Web of Science ®Google Scholar
• OpitzCFWenselRBettmannMSchaffarczykRLinscheidMHetzerRAssessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalationEur Heart J200324435636512581683
   PubMed Web of Science ®Google Scholar
• De LucaDZeccaEPiastraMRomagnoliCIloprost as ‘rescue’ therapy for pulmonary hypertension of the neonatePaediatr Anaesth200717439439517359413
   PubMedGoogle Scholar
• ChotigeatUJaratwashirakulSInhaled iloprost for severe persistent pulmonary hypertension of the newbornJ Med Assoc Thai200790116717017621749
   PubMedGoogle Scholar
• EifingerFSreeramNMehlerKHuenselerCKribsARothBAerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot studyKlin Padiatr20082202666917710738
   PubMedGoogle Scholar
• ZwisslerBRankNJaenickeUSchürleBWelteMReichartBSelective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypassAnesthesiology199582151215167793663
   PubMedGoogle Scholar
• SitbonOBrenotFDenjeanABergeronAParentFAzarianRInhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertensionAm J Respir Crit Care Med19951513843897842196
   PubMed Web of Science ®Google Scholar
• RobertsJDJrLangPBigatelloLMVlahakesGJZapolWMInhaled nitric oxide in congenital heart diseaseCirculation19938724474538425292
   PubMedGoogle Scholar
• HoeperMMOlschewskiHGhofraniHAWilkensHWinklerJBorstMMA comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study groupJ Am Coll Cardiol2035117618210636277
   PubMedGoogle Scholar
• BernerMBeghettiMSpahr-SchopferIOberhansliIFriedliBInhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart diseaseAm J Cardiol19967775325358629600
   PubMedGoogle Scholar
• RimensbergerPCSpahr-SchopferIBernerMJaeggiEKalangosAFriedliBInhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanismsCirculation2001103454454811157720
   PubMed Web of Science ®Google Scholar
• HalliogluODilberECelikerAComparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart diseaseAm J Cardiol20039281007100914556887
   PubMed Web of Science ®Google Scholar